- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Mo | Psyence Biomedical Ltd.: Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development | 178 | GlobeNewswire (Europe) | HIGHLIGHTS Texas-based company established as dedicated U.S. vehicle for regulated ibogaine developmentPositioned to hold U.S. rights to PsyLabs' pharmaceutical-grade ibogaine, subject to completion... ► Artikel lesen | |
| 08.09. | Eli Lilly, AbbVie und Johnson & Johnson: Wie der Fünf-Milliarden-Dollar-Pharma-Run auf Psychedelika Emyria in den Fokus rückt | Small- & Micro Cap Investment | |||
| 18.08. | Psyence BioMed responds to Trump ibogaine announcement | 2 | Investing.com | ||
| 18.08. | Psyence BioMed positioniert sich nach Trump-Ankündigung zu Ibogain | 4 | Investing.com Deutsch | ||
| 18.08. | Psyence Biomedical Ltd.: Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development | 258 | GlobeNewswire (Europe) | NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company focused on the development and supply of nature-derived... ► Artikel lesen | |
| PSYENCE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 18.08. | Trump-Ankündigung zu Ibogain lässt Aktie von Psyence Biomedical haussieren | 2 | Investing.com Deutsch | ||
| 06.08. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 22.06. | PSYENCE BIOMEDICAL LTD. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 05.06. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.05. | Psyence Biomedical Ltd.: Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing | 1 | GlobeNewswire (USA) | ||
| 23.04. | Psyence Biomedical doses first patient in psilocybin cancer trial | 2 | Investing.com | ||
| 23.04. | Psyence Biomedical startet Phase-IIb-Studie mit Psilocybin bei Krebspatienten | 2 | Investing.com Deutsch | ||
| 23.04. | Psyence Biomedical Ltd.: Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder | 360 | GlobeNewswire (Europe) | NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company developing nature-derived psychedelic... ► Artikel lesen | |
| 20.04. | Psyence Biomedical Ltd.: Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source | 18 | GlobeNewswire (USA) | ||
| 17.04. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.04. | Psyence Biomedical Stock Surges 42% On Growing Interest In Ibogaine Research | 3 | RTTNews | ||
| 17.04. | Psyence Biomedical Ltd.: Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine | 703 | GlobeNewswire (Europe) | NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin... ► Artikel lesen | |
| 17.04. | Morning Market Movers: Psyence Biomedical, WeShop, Julong Holding, Lifezone Metals See Big Swings | 2.981 | AFX News | BEIJING (dpa-AFX) - At 7:55 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 08.04. | Psyence Biomedical expands Australian clinical sites to five | 2 | Investing.com |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 2,490 | +2,47 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| IMMATICS | 7,525 | +0,87 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| TRAWS PHARMA | 0,516 | -0,48 % | Traws Pharma, Inc.: Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights | Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge studyCompleted the April 2026 private... ► Artikel lesen | |
| CURIS | 0,915 | 0,00 % | Curis, Inc. Announces Pricing of $5.6 Million Public Offering | LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| GENPREX | 3,510 | +1,74 % | Genprex, Inc.: Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy | Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials
AUSTIN, Texas, Aug. 18, 2026... ► Artikel lesen | |
| TVARDI THERAPEUTICS | 1,430 | -7,74 % | Lucid Capital Markets initiates Tvardi stock with buy rating | ||
| ALAUNOS THERAPEUTICS | 1,490 | +2,05 % | Alaunos Therapeutics, Inc.: Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study | This statistical finding supports a lower liver-weight signal after adjustment for body fat percentage, suggesting the finding was not fully explained by measured body fat in this modelLiver-weight... ► Artikel lesen | |
| AINOS | 1,370 | 0,00 % | Ainos, Inc.: Ainos Advances AI Nose into Commercial Deployment in Front-End Semiconductor Manufacturing | Initial commercial orders mark progress toward broader commercial adoption and support revenue-generation opportunities beginning in 2H 2026Proprietary real-world chemical dataset surpasses 1 billion... ► Artikel lesen | |
| MATINAS BIOPHARMA | 0,191 | 0,00 % | Matinas BioPharma Holdings, Inc.: Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards | BEDMINSTER, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the "Company") (NYSE American: MTNB) announced today that on August 31, 2026, it received a notice (the "Notice")... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 1,500 | 0,00 % | Morning Market Movers: Huachen AI Parking, FatPipe, Enveric Biosciences, Akanda See Big Swings | TEL AVIV (dpa-AFX) - At 8:00 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 3,760 | 0,00 % | Neuphoria Therapeutics, Inc.: Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc | Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria"... ► Artikel lesen | |
| SCINAI IMMUNOTHERAPEUTICS LTD | 2,440 | 0,00 % | Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business | ||
| CLEARMIND MEDICINE | 0,917 | -2,82 % | Clearmind Medicine Inc.: Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial | Vancouver, Canada, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived... ► Artikel lesen | |
| NIKI BIOSOLUTIONS | 5,840 | 0,00 % | Niki BioSolutions, Inc.: Niki BioSolutions Accelerates Its Alzheimer's Disease Testing Pipeline Through Strategic Bioinformatics and Statistical Analysis Partnership with Fios Genomics | Advanced multi-omics data analysis and biostatistical expertise to sharpen target and biomarker decisions across the platform PRINCETON, N.J., and NEW HAVEN, Conn., Sept. 14, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| ABVC BIOPHARMA | 1,000 | 0,00 % | EQS-News: ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders | EQS-News: ABVC BioPharma, Inc.
/ Key word(s): Manufacturing
ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares... ► Artikel lesen |
Das Unternehmen PSYENCE BIOMEDICAL LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,33 % bei einem Aktienkurs von 5,980 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE BIOMEDICAL LTD finden Sie auf Wallstreet Online.